Buprenorphine induction typically requires that a patient experience moderate opioid withdrawal before starting the medication in order to avoid precipitating severe withdrawal symptoms. This waiting period is uncomfortable and can be a treatment barrier. In this study, researchers develop and test an induction protocol using injectable buprenorphine that gets around this initial waiting period.

A new long-acting injectable formulation of buprenorphine, Brixadi, is now available for the treatment of opioid use disorder. It is the second one to hit the market, after Sublocade. The two formulations share similarities, but there are some important differences to consider when choosing which medication to prescribe.

Psychotherapy and medication management are the two cornerstones of addiction treatment, but they are not equally effective across different substance use disorders. This article reviews evidence from both therapeutic approaches and introduces the concept of a treatment spectrum, with medication on one end and therapy on the other. This spectrum can be a useful framework when discussing treatment options with patients and in treatment planning.

Injectable naltrexone can be an effective treatment for opioid use disorder, but it requires complete abstinence before initiation—a process that can take more than a week and cause significant discomfort. Here, researchers evaluate a new protocol designed to accelerate this induction period and improve patient access.